Conatus Pharmaceuticals (Conatus Pharmaceuticals) Accounts Payable : $0.00 Mil (As of Mar. 2020)

View and export this data going back to 2013. Start your Free Trial

What is Conatus Pharmaceuticals Accounts Payable?

Conatus Pharmaceuticals's Accounts Payable for the quarter that ended in Mar. 2020 was $0.00 Mil.

Conatus Pharmaceuticals Accounts Payable Historical Data

The historical data trend for Conatus Pharmaceuticals's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Conatus Pharmaceuticals Accounts Payable Chart

Conatus Pharmaceuticals Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Accounts Payable

Get a 7-Day Free Trial

Conatus Pharmaceuticals Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20
Accounts Payable	Get a 7-Day Free Trial															-	-	-	-	-

Conatus Pharmaceuticals Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Conatus Pharmaceuticals Accounts Payable Related Terms

Thank you for viewing the detailed overview of Conatus Pharmaceuticals's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Conatus Pharmaceuticals (Conatus Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Conatus Pharmaceuticals Inc (NAS:CNAT) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

16745 West Bernardo Drive, Suite 250, San Diego, CA, USA, 92127

Website

https://www.conatuspharma.com

Conatus Pharmaceuticals Inc is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need. The company is developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease. Emricasan is designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis. Conatus has also been developing CTS-2090, an orally active selective caspase inhibitor, for diseases involving inflammasome pathways.